AnaptysBio 향후 성장

Future 기준 점검 3/6

AnaptysBio (는) 각각 연간 21.1% 및 20.2% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 32.7% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 78.6% 로 예상됩니다.

핵심 정보

21.1%

이익 성장률

32.74%

EPS 성장률

Biotechs 이익 성장	23.1%
매출 성장률	20.2%
향후 자기자본이익률	78.62%
애널리스트 커버리지	Good
마지막 업데이트	10 Dec 2025

최근 향후 성장 업데이트

Earnings Update: AnaptysBio, Inc. (NASDAQ:ANAB) Just Reported And Analysts Are Boosting Their Estimates

May 08

Recent updates

AnaptysBio: Maintaining 'Hold' As RA Program Still In Play With ANB033 Advancement

Nov 13

AnaptysBio, Inc.'s (NASDAQ:ANAB) Share Price Not Quite Adding Up

Jul 16

Shareholders May Be More Conservative With AnaptysBio, Inc.'s (NASDAQ:ANAB) CEO Compensation For Now

Jun 11

Earnings Update: AnaptysBio, Inc. (NASDAQ:ANAB) Just Reported And Analysts Are Boosting Their Estimates

May 08

Is AnaptysBio (NASDAQ:ANAB) Using Debt Sensibly?

May 07

AnaptysBio, Inc.'s (NASDAQ:ANAB) Price Is Right But Growth Is Lacking After Shares Rocket 30%

Apr 03

AnaptysBio: A Shadow Of Its Former Self

Mar 06

AnaptysBio, Inc. (NASDAQ:ANAB) Stock Rockets 29% As Investors Are Less Pessimistic Than Expected

Feb 14

AnaptysBio: Doubts About Cash And Upcoming Rheumatoid Arthritis Readout

Dec 18

AnaptysBio: An Immunology Pipeline-In-A-Pill Company Worth Watching

Nov 21

AnaptysBio, Inc. (NASDAQ:ANAB) May Have Run Too Fast Too Soon With Recent 33% Price Plummet

Nov 07

News Flash: Analysts Just Made A Captivating Upgrade To Their AnaptysBio, Inc. (NASDAQ:ANAB) Forecasts

May 22

Earnings Update: AnaptysBio, Inc. (NASDAQ:ANAB) Just Reported And Analysts Are Boosting Their Estimates

May 12

Does AnaptysBio (NASDAQ:ANAB) Have A Healthy Balance Sheet?

Feb 22

Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation

Oct 10

AnaptysBio, Inc. (NASDAQ:ANAB) Analysts Just Trimmed Their Revenue Forecasts By 12%

May 24

Is AnaptysBio (NASDAQ:ANAB) In A Good Position To Deliver On Growth Plans?

Apr 27

Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation

Jan 10

이익 및 매출 성장 예측

NasdaqGS:ANAB - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)
날짜	매출	이익	자유현금흐름	영업현금흐름	평균 애널리스트 수
12/31/2028	264	-90	-94	-305	7
12/31/2027	168	-189	-39	-97	8
12/31/2026	127	-131	-73	-48	10
12/31/2025	205	-39	-24	-62	10
9/30/2025	169	-85	-145	-145	N/A
6/30/2025	123	-133	-128	-128	N/A
3/31/2025	112	-141	-109	-109	N/A
12/31/2024	91	-145	-136	-135	N/A
9/30/2024	57	-166	-103	-103	N/A
6/30/2024	30	-170	-130	-129	N/A
3/31/2024	23	-163	-134	-133	N/A
12/31/2023	17	-164	-122	-121	N/A
9/30/2023	15	-148	-98	-97	N/A
6/30/2023	13	-144	-79	-78	N/A
3/31/2023	11	-137	-78	-77	N/A
12/31/2022	10	-129	-74	-74	N/A
9/30/2022	4	-135	-88	-88	N/A
6/30/2022	24	-108	-78	-77	N/A
3/31/2022	53	-76	-45	-44	N/A
12/31/2021	63	-58	-47	-46	N/A
9/30/2021	122	8	15	17	N/A
6/30/2021	101	-9	5	7	N/A
3/31/2021	71	-30	-23	-22	N/A
12/31/2020	75	-20	-15	-14	N/A
9/30/2020	18	-74	-68	-68	N/A
6/30/2020	18	-81	-73	-73	N/A
3/31/2020	23	-84	-69	-69	N/A
12/31/2019	8	-97	-70	-70	N/A
9/30/2019	5	-94	-67	-66	N/A
6/30/2019	10	-79	N/A	-59	N/A
3/31/2019	5	-69	N/A	-52	N/A
12/31/2018	5	-62	N/A	-49	N/A
9/30/2018	8	-52	N/A	-41	N/A
6/30/2018	3	-45	N/A	-30	N/A
3/31/2018	10	-34	N/A	-24	N/A
12/31/2017	10	-30	N/A	-19	N/A
9/30/2017	10	-27	N/A	-20	N/A
6/30/2017	13	-19	N/A	-19	N/A
3/31/2017	12	-15	N/A	-15	N/A
12/31/2016	17	-4	N/A	-9	N/A
9/30/2016	18	-4	N/A	-6	N/A
6/30/2016	19	-4	N/A	-5	N/A
3/31/2016	18	-6	N/A	-9	N/A
12/31/2015	18	-5	N/A	-10	N/A
9/30/2015	17	-2	N/A	-6	N/A
6/30/2015	19	0	N/A	-4	N/A
3/31/2015	18	1	N/A	-3	N/A

애널리스트 향후 성장 전망

수입 대 저축률: ANAB 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: ANAB 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: ANAB 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: ANAB 의 수익(연간 20.2%)이 US 시장(연간 10.4%)보다 빠르게 성장할 것으로 예상됩니다.

고성장 매출: ANAB 의 수익(연간 20.2%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: ANAB의 자본 수익률은 3년 후 78.6%로 매우 높을 것으로 예상됩니다.

성장 기업 찾아보기

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2025/12/31 20:09
종가	2025/12/31 00:00
수익	2025/09/30
연간 수익	2024/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 Github 페이지에서 확인할 수 있으며, 보고서 활용 방법에 대한 가이드와 Youtube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

AnaptysBio, Inc.는 21명의 분석가가 다루고 있습니다. 이 중 10명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Neena Bitritto-Garg	Baird
Etzer Darout	Barclays
Michael King	Citizens JMP Securities, LLC

AnaptysBio 향후 성장

Future 기준 점검 3/6

핵심 정보

최근 향후 성장 업데이트

Price target decreased by 7.3% to US$45.40

Price target increased by 11% to US$45.55

Price target increased by 9.2% to US$41.09

Consensus revenue estimates increase by 24%, EPS downgraded

Earnings Update: AnaptysBio, Inc. (NASDAQ:ANAB) Just Reported And Analysts Are Boosting Their Estimates

Consensus revenue estimates increase by 16%

Recent updates

Chief Legal Officer notifies of intention to sell stock

Independent Director recently sold US$193k worth of stock

AnaptysBio, Inc. Files a Verified Complaint in Delaware Chancery Court, Requesting a Court Declaration That TESARO, Inc

AnaptysBio: Maintaining 'Hold' As RA Program Still In Play With ANB033 Advancement

Anaptys Announces Phase 2 Trial of Rosnilimab Did Not Meet Primary or Secondary Endpoints At Week 12 in Moderate-To-Severe Ulcerative Colitis

AnaptysBio, Inc. Announces New Positive Phase 2b Trial Results for Rosnilimab in Rheumatoid Arthritis at ACR Late-Breaking Oral Presentation

Anaptys Announces Late-Breaking Oral Presentation of Complete Phase 2b Data for Rosnilimab in Rheumatoid Arthritis at Upcoming ACR Convergence 2025

AnaptysBio, Inc. Announces Intent to Separate Biopharma Operations from Substantial Royalty Assets by Year-End 2026

Lead Independent Director exercised options and sold US$130k worth of stock

Price target decreased by 7.3% to US$45.40

New major risk - Negative shareholders equity

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

Price target increased by 11% to US$45.55

AnaptysBio, Inc.'s (NASDAQ:ANAB) Share Price Not Quite Adding Up

Lead Independent Director exercised options and sold US$348k worth of stock

Shareholders May Be More Conservative With AnaptysBio, Inc.'s (NASDAQ:ANAB) CEO Compensation For Now

Anaptys Announces Positive Rosilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA

Price target increased by 9.2% to US$41.09

Consensus revenue estimates increase by 24%, EPS downgraded

Earnings Update: AnaptysBio, Inc. (NASDAQ:ANAB) Just Reported And Analysts Are Boosting Their Estimates

Is AnaptysBio (NASDAQ:ANAB) Using Debt Sensibly?

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

AnaptysBio, Inc., Annual General Meeting, Jun 17, 2025

AnaptysBio, Inc.'s (NASDAQ:ANAB) Price Is Right But Growth Is Lacking After Shares Rocket 30%

Consensus revenue estimates increase by 16%

AnaptysBio, Inc. (NasdaqGS:ANAB) announces an Equity Buyback for $75 million worth of its shares.

Consensus revenue estimates increase by 14%

AnaptysBio: A Shadow Of Its Former Self

New minor risk - Shareholder dilution

Price target increased by 7.9% to US$37.09

Full year 2024 earnings: EPS and revenues exceed analyst expectations

New major risk - Share price stability

AnaptysBio, Inc. (NASDAQ:ANAB) Stock Rockets 29% As Investors Are Less Pessimistic Than Expected

Anaptys Announces Rosnilimab Achieves Positive Results in Ra Phase 2B Trial and Highest Ever Reported Cdai Lda Response over 6 Months

Independent Director exercised options to buy US$636k worth of stock.

President exercised options and sold US$288k worth of stock

AnaptysBio: Doubts About Cash And Upcoming Rheumatoid Arthritis Readout

Price target decreased by 14% to US$47.90

Anaptys Announces Phase 2B Trial of ANB032, A Btla Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis

Lead Independent Director exercised options and sold US$181k worth of stock

AnaptysBio: An Immunology Pipeline-In-A-Pill Company Worth Watching

AnaptysBio, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Consensus revenue estimates increase by 70%

AnaptysBio, Inc. (NASDAQ:ANAB) May Have Run Too Fast Too Soon With Recent 33% Price Plummet

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

AnaptysBio: Too Risky, Especially After GSK Drops Its Related Programs

Chief Legal Officer notifies of intention to sell stock

Chief Financial Officer notifies of intention to sell stock

AnaptysBio: Top-Line AD Data End Of 2024 Could Be Turning Point

AnaptysBio, Inc. has filed a Follow-on Equity Offering in the amount of $100.393177 million.

Consensus revenue estimates fall by 20%

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Price target increased by 10% to US$48.22

AnaptysBio: Interesting Prospects, But Wait For The Dip (Rating Downgrade)

News Flash: Analysts Just Made A Captivating Upgrade To Their AnaptysBio, Inc. (NASDAQ:ANAB) Forecasts

Earnings Update: AnaptysBio, Inc. (NASDAQ:ANAB) Just Reported And Analysts Are Boosting Their Estimates

New minor risk - Shareholder dilution

Anaptys Announces Positive Top-Line Gemini-2 Phase 3 Clinical Trial Results of imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus revenue estimates increase by 11%

AnaptysBio, Inc., Annual General Meeting, Jun 12, 2024

President recently sold US$3.4m worth of stock

Consensus revenue estimates increase by 48%

Full year 2023 earnings: EPS in line with analyst expectations despite revenue beat

Does AnaptysBio (NASDAQ:ANAB) Have A Healthy Balance Sheet?

Chief Legal Officer notifies of intention to sell stock

No longer forecast to breakeven

Price target increased by 27% to US$35.83

President exercised options and sold US$150k worth of stock